RecruitingNCT04953273
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FrancePTSDInterventional studyAges 18+
- Countries
- France
- Sponsor
- University Hospital, Lille
RecruitingNCT06733974
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FrancePTSDInterventional studyAges 18+
- Countries
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
RecruitingNCT01248767
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceAddictionObservational studyAges 15+
- Countries
- France
- Sponsor
- Nantes University Hospital
RecruitingNCT05511363
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceSchizophreniaMedication studyAges 55–90
- Countries
- France, United States, United Kingdom, + 10 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT06887192
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceSchizophreniaMedication studyAges 55–90
- Countries
- France, United States, Canada, + 12 others
- Sponsor
- MapLight Therapeutics
RecruitingNCT06929273
What is this study about?This extension study evaluates the long-term safety and tolerability of KarXT for mania or mania with mixed features in people living with bipolarity type I.
In FranceBipolarityMedicationAges 18–65
- Countries
- France, United States, Australia, + 17 others
- Sponsor
- Bristol-Myers Squibb
RecruitingNCT06585787
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceSchizophreniaMedication studyAges 55–90
- Countries
- France, United States, Belgium, + 21 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT07140913
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
Location not clearly listedBipolarityMedication studyAges 18–65
- Countries
- France, United States, Argentina, + 10 others
- Sponsor
- Bristol-Myers Squibb
RecruitingNCT07424404
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
Location not clearly listedSchizophreniaMedication studyAges 5–17
- Countries
- France, United States, Australia, + 7 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT05361603
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceAddictionObservational studyAges 18+
- Countries
- France
- Sponsor
- University Hospital, Limoges
RecruitingNCT06159673
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
Location not clearly listedSchizophreniaMedication studyAges 55–95
- Countries
- France, United States, Brazil, + 9 others
- Sponsor
- ACADIA Pharmaceuticals Inc.
RecruitingNCT07193914
What is this study about?A short description of this study's objective has not yet been verified by HopeStage.
In FranceAddiction, PTSDInterventional studyAges 18+
- Countries
- France
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Data coveragePublic registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.